Results of the GA-40 Studies

​

​

Preclinical and clinical trials in 8 different countries have confirmed the quality, safety and effectiveness of GA-40.

 

 

GA-40 has passed preclinical and clinical trials in the following organizations:

 

• Medical and biological research center - LLC Company "Alexis".

• National Cancer Center named after Gvamichava.

• Clinical Experimental Research Institute of Tbilisi State Medical University.

• Skin and Venereal Dispensary No. 1 of the Ministry of Labor, Health and Social Protection of Georgia.

• Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine.

• Department of Biochemistry, Ukrainian State University.

• Bukovina State Medical University, Chernivtsi, Ukraine.

• Cancer Center of the Ukrainian Medical Academy, Ukraine.

• Laboratory of Cellular Signaling Mechanisms. Paladin of the National Academy of Sciences of Ukraine.

• Medical Research Institute of Physical Chemistry, Ministry of Health of Russia, Russian Federation.

• Department of Pharmacology, Medical University of the Russian Federation, Russian Federation.

• Pharmaceutical company Otsuka, Japan.

• Tokushima Institute of Cell Technology, Japan.

• Fuji Memorial Institute for Preclinical Research, Biwako, Japan.

• Research Institute for New Drugs Research and Safety Assessment, Tokushima, Japan.

• University of Washington, School of Medicine, Department of Cancer Research, Department of Pathology, Seattle, USA.

• Center for Quantum Genetics, Diagnostics and Therapy "Molecule", Zagreb, Croatia.

• Pharmaceutical company Follium xp, California, USA.

• Pharmaceutical division of the "Mega Alliance" Co., Zurich, Switzerland.